Pamela Theriot
Optometrist · Shreveport, LANPI 1194823336
Payments from drug & device makers
Across 702 payments — averaging $295.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$97K
- Sun Pharmaceutical Industries Inc.$43K
- Alcon$30K
- Johnson & Johnson Surgical Vision, Inc.$10K
- Tarsus Pharmaceuticals, Inc.$7K
- Lumenis BE Inc$4K
- plus $16K from 23 others
What the payments were for
- Consulting fees$20,31510%
- Speaking & faculty fees$131,79664%
- Travel & lodging$32,87616%
- Food & beverage$22,16111%
- Education$980%
- Entertainment$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 197 | $97,265 |
| Sun Pharmaceutical Industries Inc. | 122 | $43,201 |
| Alcon | 73 | $30,029 |
| Johnson & Johnson Surgical Vision, Inc. | 17 | $9,599 |
| Tarsus Pharmaceuticals, Inc. | 44 | $7,050 |
| Lumenis BE Inc | 4 | $4,195 |
| Biotissue Holdings Inc. | 25 | $2,533 |
| Mallinckrodt Hospital Products Inc. | 15 | $2,349 |
| Novartis | 34 | $1,814 |
| Dompe US, Inc. | 8 | $1,629 |
| AbbVie(2 entities) | 48 | $1,435 |
| Sight Sciences, Inc. | 8 | $1,303 |
| Alcon Research LLC | 2 | $1,200 |
| Bausch & Lomb Americas Inc. | 25 | $1,126 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $433 |
| Amgen(2 entities) | 12 | $416 |
| Thea Pharma Inc. | 7 | $374 |
| Kala Pharmaceuticals, Inc. | 18 | $364 |
| Aerie Pharmaceuticals, Inc. | 14 | $333 |
| Optos, Inc. | 2 | $192 |
| Harrow Eye, LLC | 6 | $144 |
| Eyevance Pharmaceuticals LLC | 1 | $94 |
| Shire North American Group Inc | 5 | $93 |
| Coopervision Inc. | 1 | $46 |
| Johnson & Johnson Vision Care, Inc. | 1 | $25 |
| Ivantis, Inc | 1 | $25 |
| Heidelberg Engineering, Inc. | 1 | $25 |
| Akorn, Inc. | 1 | $17 |
| Rxsight Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$94,249
- CEQUA$41,412
- TRYPTYR$27,055
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$8,249
- Tecnis IOL$2,778
- XDEMVY$2,759
- optilight$2,460
- ACTHAR$1,980
- Prokera$1,768
- AmnioGraft$1,768
- M22$1,735
- Oxervate$1,356
- TearCare$1,000
- Tecnis Simplicity$926
- XIIDRA$922
- AIR OPTIX$783
- DAILIES$522
- VUITY$375
- MIEBO$264
- PANORAMIC OPHTHALMOSCOPE$237
How this compares
$207,319 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 42 | $1,507,237 |
| XdemvyLotilaner | 70 | $130,766 |
| RestasisCyclosporine | 54 | $71,782 |
| XiidraLifitegrast | 29 | $40,768 |
| CequaCyclosporine | 23 | $19,522 |
| Cyclosporine | 22 | $16,633 |
| TyrvayaVarenicline Tartrate | 24 | $15,206 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,207 |
| Loteprednol Etabonate | 49 | $8,359 |
| Alphagan PBrimonidine Tartrate | 17 | $3,555 |
| Fluorometholone | 27 | $2,096 |
| Brimonidine Tartrate | 28 | $1,926 |
| Fml ForteFluorometholone | 11 | $1,767 |
| Prednisolone Acetate | 36 | $1,433 |
| Doxycycline Hyclate | 18 | $1,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $1,629 | $1,507,23742 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $7,050 | $130,76670 claims |
| AbbVieRestasis, Alphagan P | $1,435 | $75,33771 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,126 | $52,97546 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $43,201 | $19,52223 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $97,265 | $15,20624 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $433 | $8,35949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Shreveport
- Stephen LewisShreveport$37K
- Sam SilverblattShreveport$6K
- Christine DavisShreveport$6K
- Gabrielle BoydShreveport$5K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Jason AllemondZachary$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.